Changes in choriocapillaris blood flow following antiangiogenic therapy in neovascular age-related macular degeneration: a prospective cohort study
Ophthalmology Reports · 30.06.2026 · 19 (2) · 7-16
DOI: 10.17816/ov701697 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Ophthalmology Reports, online erschienen am 30.06.2026. Verfasst von Natalia A. Gavrilova und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Despite the proven effectiveness of intravitreal administration of medications that inhibit vascular endothelial growth factor, the mechanisms through which these agents affect choroidal microcirculation, particularly the perfusion characteristics of the choriocapillaris in the early period after treatment initiation, require further investigation. This study was undertaken to provide a detailed description of the temporal dynamics of choriocapillaris perfusion using a high-frequency monitoring protocol based on optical coherence tomography angiography and an improved image-analysis method aimed at minimizing visualization artifacts. AIM: To perform a quantitative topographical analysis of changes in choriocapillaris perfusion following antiangiogenic therapy with aflibercept in patients with neovascular age-related macular degeneration. METHODS: A prospective, single-center cohort study involved patients with newly diagnosed active type 1 macular neovascularization, who were treatment-naïve, including antiangiogenic therapy–naïve ones. Exclusion criteria were type 2 or 3 macular neovascularization; moderate-to-high myopia or hyperopia; significant ocular media opacities; concomitant systemic or ocular conditions associated with shadowing artifacts; and retinal pigment epithelium detachment height 250 µm. All participants received three intravitreal injections of aflibercept (2.0 mg) at monthly intervals. Choriocapillaris perfusion changes were assessed using a high-frequency monitoring protocol with biweekly examinations over 12 weeks. We applied an enhanced choriocapillaris image-analysis method that reduced projection artifacts and compensated for signal attenuation. Statistical analysis included repeated-measures analysis of variance and paired t-tests. RESULTS: The mean patient age was 70.8 ± 7.1 years; women accounted for 63.0%. All 29 participants completed follow-up. By week 12, a significant reduction in the FD% was observed in all regions (ANOVA: p 0.001; paired comparisons between baseline and week 12: p 0.001); the mean relative reduction was 9.8%, with the largest changes in peripheral zones R3–R5. No treatment-related adverse events were recorded. CONCLUSION: High-frequency monitoring using an enhanced optical coherence tomography angiography protocol confirmed a significant improvement in choriocapillaris perfusion surrounding the macular neovascularization and the associated "dark halo" in patients with neovascular age-related macular degeneration treated with aflibercept. These findings improve the understanding of the microcirculatory effects of antiangiogenic therapy and support the potential value of this approach for treatment response assessment in routine clinical practice.
Zitieren
APA
Gavrilova, N. A., & Gabaraev, G. M. (2026). Changes in choriocapillaris blood flow following antiangiogenic therapy in neovascular age-related macular degeneration: a prospective cohort study. Ophthalmology Reports, 19(2), 7-16. https://doi.org/10.17816/ov701697
Vancouver
Gavrilova NA, Gabaraev GM. Changes in choriocapillaris blood flow following antiangiogenic therapy in neovascular age-related macular degeneration: a prospective cohort study. Ophthalmology Reports. 2026;19(2):7-16. doi:10.17816/ov701697
BibTeX
@article{Gavrilova2026,
author = {Gavrilova, Natalia A. and Gabaraev, Georgiy M.},
title = {Changes in choriocapillaris blood flow following antiangiogenic therapy in neovascular age-related macular degeneration: a prospective cohort study},
journal = {Ophthalmology Reports},
year = {2026},
volume = {19},
number = {2},
pages = {7--16},
doi = {10.17816/ov701697}
}
EUVIMED